NCT00627978View on ClinicalTrials.gov

Phase II Study of Ixabepilone in Metastatic Breast Cancer and Its Effects on the Ultrastructure of Neurons

PHASE2CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

November 30, 2007

Primary Completion Date

January 31, 2011

Study Completion Date

January 31, 2011

Conditions
Metastatic Breast Cancer
Interventions
DRUG

ixabepilone

ixabepilone 40 mg/m2 Q3w over 3 hours

Trial Locations (1)

10021

Weill Medical College of Cornell University, New York

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Weill Medical College of Cornell University

OTHER

NCT00627978 - Phase II Study of Ixabepilone in Metastatic Breast Cancer and Its Effects on the Ultrastructure of Neurons | Biotech Hunter | Biotech Hunter